Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene® Mist
Amphastar Pharmaceuticals, Inc | December 27, 2016
Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its wholly-owned subsidiary, Armstrong Pharmaceuticals, Inc., for its New Drug Application for Primatene® Mist (epinephrine inhalation aerosol)…